坂井大介

Sakai Daisuke

所属機関・部署：
競争的資金等の研究課題 (4件)：

2018 - 2021 がん化学療法の精密医療の実現化
2018 - 2021 Warburg制御因子MPCによる早期脳転移機序の解明と応用
2016 - 2018 癌遺伝子選択性を実現するエピゲノム創薬の新展開
2014 - 2016 1型糖尿病の根治を目指した新規膵β細胞誘導物質の同定と創薬展開

論文 (151件)：

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, et al. Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902). International journal of clinical oncology. 2024. 29. 2. 134-141
Kuniko Sunami, Yoichi Naito, Yusuke Saigusa, Toraji Amano, Daisuke Ennishi, Mitsuho Imai, Hidenori Kage, Masashi Kanai, Hirotsugu Kenmotsu, Keigo Komine, et al. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA oncology. 2023
Yutaka Kimura, Hisato Kawakami, Shigeyuki Tamura, Kazumasa Fujitani, Jin Matsuyama, Hiroshi Imamura, Shohei Iijima, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, et al. Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2023. 26. 5. 788-797
Hiroki Yukami, Hisato Kawakami, Toshifumi Yamaguchi, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Masahiro Goto, Taroh Satoh. Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106). International journal of clinical oncology. 2023. 28. 9. 1176-1182
Chiaki Inagaki, Hisato Kawakami, Daichi Maeda, Daisuke Sakai, Shinya Urakawa, Kentaro Nishida, Toshihiro Kudo, Yuichiro Doki, Hidetoshi Eguchi, Hisashi Wada, et al. The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. Scientific reports. 2023. 13. 1. 5652-5652

MISC (68件)：

王谷英達, 畑毛一枝, 坂井大介, 佐藤太郎, 伊村慶紀, 中井隆彰, 名井陽, 岡田誠司. ゲノム医療時代の骨・軟部腫瘍医肉腫診療におけるがんゲノム医療の実際. 日本整形外科学会雑誌. 2022. 96. 6. S1284-S1284
Atsushi Yasuda, Jin Matsuyama, Tetsuji Terazawa, Masahiro Goto, Ryohei Kawabata, Shunji Endo, Motohiro Imano, Shoichiro Fujita, Yusuke Akamaru, Hirokazu Taniguchi, et al. A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601). JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 3
村地康, 坂井大介, 小関準, 稲垣千晶, 西田尚弘, 山口敏史, 佐藤太郎. レゴラフェニブで治療した進行・再発結腸直腸癌患者におけるサルコペニアの影響. 日本癌治療学会学術集会抄録集. 2020. 58回. P-484
Masashi Hirota, Shigeyuki Tamura, Hirokazu Taniguchi, Atsushi Takeno, Hiroshi Imamura, Junya Fujita, Jin Matsuyama, Yutaka Kimura, Junji Kawada, Motohiro Hirao, et al. A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4
Jin Matsuyama, Hisato Kawakami, Kazumasa Fujitani, Yusuke Akamaru, Shigeyuki Tamura, Shunji Endo, Yutaka Kimura, Youichi Makari, Takao Tamura, Naotoshi Sugimoto, et al. Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naive advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 4

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

坂井 大介

坂井大介